Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma.
biomarkers
digital PCR
extracellular vesicles
flow cytometry
hematological malignancies
nanoparticle tracking analysis
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
01
2021
accepted:
11
03
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are naturally secreted cellular lipid bilayer particles, which carry a selected molecular content. Owing to their systemic availability and their role in tumor pathogenesis, circulating EVs (cEVs) can be a valuable source of new biomarkers useful for tumor diagnosis, prognostication and monitoring. However, a precise approach for isolation and characterization of cEVs as tumor biomarkers, exportable in a clinical setting, has not been conclusively established. We developed a novel and laboratory-made procedure based on a bench centrifuge step which allows the isolation of serum cEVs suitable for subsequent characterization of their size, amount and phenotype by nanoparticle tracking analysis, microscopy and flow cytometry, and for nucleic acid assessment by digital PCR. Applied to blood from healthy subjects (HSs) and tumor patients, our approach permitted from a small volume of serum (i) the isolation of a great amount of EVs enriched in small vesicles free from protein contaminants; (ii) a suitable and specific cell origin identification of EVs, and (iii) nucleic acid content assessment. In clonal plasma cell malignancy, like multiple myeloma (MM), our approach allowed us to identify specific MM EVs, and to characterize their size, concentration and microRNA content allowing significant discrimination between MM and HSs. Finally, EV associated biomarkers correlated with MM clinical parameters. Overall, our cEV based procedure can play an important role in malignancy biomarker discovery and then in real-time tumor monitoring using minimal invasive samples. From a practical point of view, it is smart (small sample volume), rapid (two hours), easy (no specific expertise required) and requirements are widely available in clinical laboratories.
Identifiants
pubmed: 33994784
doi: 10.2147/IJN.S303391
pii: 303391
pmc: PMC8114829
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3141-3160Informations de copyright
© 2021 Laurenzana et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Mol Sci. 2018 Feb 03;19(2):
pubmed: 29401684
Circ Res. 2017 May 12;120(10):1632-1648
pubmed: 28495994
Leukemia. 2017 Sep;31(9):2009-2010
pubmed: 28656959
Stem Cells Int. 2018 May 27;2018:9863194
pubmed: 29977309
Front Pharmacol. 2016 Nov 07;7:416
pubmed: 27872592
Ann Oncol. 2016 Apr;27(4):635-41
pubmed: 26681674
Cells. 2019 Aug 20;8(8):
pubmed: 31434250
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Thromb Haemost. 2014 Jul;12(7):1182-92
pubmed: 24818656
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Cancer Cell Int. 2019 Dec 18;19:341
pubmed: 31866766
Expert Rev Mol Diagn. 2016 Jun;16(6):623-9
pubmed: 27043038
Clin Chem. 2020 Jan 1;66(1):89-96
pubmed: 31811003
J Clin Med. 2019 Mar 18;8(3):
pubmed: 30889786
Haematologica. 2008 Mar;93(3):431-8
pubmed: 18268286
J Cancer Res Clin Oncol. 2016 Jan;142(1):101-10
pubmed: 26115960
Blood. 2007 Aug 15;110(4):1330-3
pubmed: 17496199
Int J Mol Sci. 2017 May 09;18(5):
pubmed: 28486431
Tumour Biol. 2015 Dec;36(12):9739-52
pubmed: 26156801
Front Neurosci. 2019 Apr 15;13:344
pubmed: 31037054
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
Blood. 2014 Oct 2;124(14):2262-70
pubmed: 25150298
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Int J Mol Sci. 2017 Jun 02;18(6):
pubmed: 28574430
Biotechnol J. 2019 Jan;14(1):e1700716
pubmed: 29878510
J Biol Chem. 2014 Feb 14;289(7):3869-75
pubmed: 24398677
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
J Extracell Vesicles. 2020 Apr 14;9(1):1750202
pubmed: 32363013
Diagnostics (Basel). 2018 May 09;8(2):
pubmed: 29747380
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
Cancer Med. 2018 Nov;7(11):5439-5447
pubmed: 30264478
Microsc Res Tech. 2007 Oct;70(10):912-7
pubmed: 17726693
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Cancer Biol Ther. 2017 Mar 4;18(3):158-165
pubmed: 28121262
Sci Rep. 2020 Jan 23;10(1):1039
pubmed: 31974468
Blood. 2009 Jan 29;113(5):1112-21
pubmed: 18802008
Theranostics. 2019 Jan 1;9(1):196-209
pubmed: 30662562
Transfus Apher Sci. 2015 Oct;53(2):110-26
pubmed: 26603057
Clin Cancer Res. 2013 Apr 15;19(8):2096-106
pubmed: 23446999
Br J Cancer. 2020 Mar;122(6):801-811
pubmed: 31937922
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
PLoS One. 2015 Jan 14;10(1):e0116812
pubmed: 25587983
Blood. 2017 Apr 27;129(17):2429-2436
pubmed: 28213378
Blood. 1999 Dec 1;94(11):3791-9
pubmed: 10572093
Leukemia. 2009 Feb;23(2):215-24
pubmed: 19020545
Mol Cancer. 2019 Apr 6;18(1):83
pubmed: 30954079
Sci Rep. 2018 Nov 6;8(1):16389
pubmed: 30401891
Int J Hematol. 2018 Oct;108(4):402-410
pubmed: 29959746
Cytometry A. 2016 Feb;89(2):184-95
pubmed: 25857288
Nat Commun. 2011 Feb 01;2:180
pubmed: 21285958
Cells. 2019 Dec 13;8(12):
pubmed: 31847204
Stem Cells Dev. 2017 Jan 1;26(1):4-14
pubmed: 27762728
J Extracell Vesicles. 2014 Aug 06;3:
pubmed: 25147646
Clin Cancer Res. 2018 Jan 1;24(1):181-188
pubmed: 29051321
J Extracell Vesicles. 2019 Jan 21;8(1):1560808
pubmed: 30719239
J Extracell Vesicles. 2020 Jan 7;9(1):1710020
pubmed: 32002172
Leuk Lymphoma. 2017 Jun;58(6):1424-1432
pubmed: 27739922
Ann Lab Med. 2018 Jan;38(1):1-8
pubmed: 29071812
Biochim Biophys Acta Biomembr. 2019 Jan;1861(1):236-244
pubmed: 30040926
Biomed Rep. 2016 Oct;5(4):395-402
pubmed: 27699004
Curr Opin Hematol. 2015 Sep;22(5):437-44
pubmed: 26214207
J Neural Transm (Vienna). 2010 Jan;117(1):1-4
pubmed: 19680595
Sci Rep. 2016 Apr 18;6:24316
pubmed: 27087061
Expert Rev Mol Diagn. 2019 Mar;19(3):249-258
pubmed: 30782029
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
Neoplasia. 2016 Jan;18(1):25-32
pubmed: 26806349
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):109-116
pubmed: 30528756
J Extracell Vesicles. 2016 Oct 31;5:32945
pubmed: 27802845
J Clin Invest. 2019 Dec 2;129(12):5518-5536
pubmed: 31710308
Anal Chem. 2011 Nov 15;83(22):8604-10
pubmed: 22035192
Mol Med Rep. 2015 Aug;12(2):1810-6
pubmed: 25825239
Front Oncol. 2014 Jun 04;4:129
pubmed: 24926435
N Engl J Med. 2018 Sep 06;379(10):958-966
pubmed: 30184457
Cell Tissue Res. 2010 Jan;339(1):31-46
pubmed: 19597846
Sci Adv. 2020 Oct 2;6(40):
pubmed: 33008904
Oncol Lett. 2020 Jan;19(1):301-308
pubmed: 31897142
Cell Oncol (Dordr). 2017 Feb;40(1):97-103
pubmed: 27761889
Front Oncol. 2019 Aug 20;9:699
pubmed: 31482061